Struthers Richard Scott's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Nov 6, 2023
- Accession no.
- 0001209191-23-054567
- Filed
- Nov 6, 2023
- Trade date
- Nov 2-3, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.11M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Struthers Richard ScottCIK 0001746298 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | Common Stock | MOption exerciseAcquired | +918 | $9.28 | +$8,519.04 | 136,440 | Direct | |
| Nov 2, 2023 | Common Stock | SSaleDisposed | −918 | $29.95 | −$27,494.1 | 135,522 | Direct | |
| Nov 3, 2023 | Common Stock | MOption exerciseAcquired | +199,082 | $9.28 | +$1,847,480.96 | 334,604 | Direct | |
| Nov 3, 2023 | Common Stock | SSaleDisposed | −199,082 | $30.56F1 | −$6,083,945.92 | 135,522 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | Common Stock | MOption exerciseDisposed | −918 | $0.00 | $0 | 363,823 | Direct | |
| Nov 3, 2023 | Common Stock | MOption exerciseDisposed | −199,082 | $0.00 | $0 | 164,741 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $30.56 per share. The range of sales prices on the transaction date was $29.95 to $31.37 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.